Clinical Trial Update: Kesimpta® (Ofatumumab) in Swiss Multiple Sclerosis Patients - an Observational Study

View source ↗

Summary

An observational study evaluating Kesimpta (ofatumumab) in Swiss patients with multiple sclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Kesimpta (ofatumumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Multiple Sclerosis | Status: COMPLETED